Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...

The reported number represents a change of +2.9% year over year. Revenue- Microarrays- Consumables: $69 million versus the two-analyst average estimate of $69.75 million. The reported number ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q3 CY2025, but sales were flat year on ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.